



Industry Highlights

- On October 1, 2019, AstraZeneca agreed to sell the global commercial rights, excluding China, Japan, the US and Mexico, for Losec and associated brands to Cheplapharm for approximately \$280 million.
- On July 1, 2019, Bristol-Myers Squibb announced it had completed its sale of its USPA consumer health business to Taisho Pharmaceutical for \$1.6 billion. The sale comes in the wake of antitrust concerns in regards to its merger with Celgene which was announced earlier in 2019. Celgene's sale of Otezla to Amgen was also in response to antitrust concerns.
- On July 15, 2019, AbbVie announced it had acquired Seattle-based Mavupharma for an undisclosed amount. Mavupharma is a biopharmaceutical company focused on novel approaches to target the genes pathway for the treatment of cancer.
- In June of 2019, Merck completed its \$773 million acquisition of biotechnology company Tilos Therapeutics.
- On July 1, 2019, Perrigo completed its acquisition of consumer oral and personal care products designer and manufacturer Ranir for \$750 million.
- On July 1, 2019, Novartis completed its acquisition of Xiidra for \$5.3 billion from Shire. Xiidra is a prescription eye drop solution designed to treat dry eye disease.
- Pfizer also completed its acquisition of Therachone AG, a biotechnology company that treats rare diseases, for \$810 million.
- Other notable deals from 2019 include Lonza Group's acquisition of the sterile drug products of Novartis, Teva's divestiture of its Over the Counter Medicine Division and Intravenous Infusions business segments, Merck completed its \$2.2 billion acquisition of Peloton Therapeutics, Mallinckrodt agreed to sell BioVectra to HIG Capital for \$250 million.


Trend in Industry EBITDA Multiples¹



Trends in Revenue Growth and EBITDA Margins¹




Relative Stock Price Returns²



¹ Calculated using aggregated data for JNJ, PFE, Novartis, MRK, ABBV, AMGN, Novo, GSK, Sanofi, LLY, GILD, BMY, LSE:AZN, AGN, MYL, TEVA, BHC, MNK, PRGO, ENDP, AMRX.

² The Pharmaceutical Industry is a custom, equal-weighted index constructed with the aforementioned companies.

Purchase Price Allocation (PPA) % from Recent Transactions



Notable M&A Deals



On July 30, 2019, Pfizer completed its acquisition of Array BioPharma for an enterprise value of approximately \$11.5 billion. Array will provide Pfizer with breakthrough science for the discovery, development, and commercialization of targeted small molecule medicines to treat cancer and other diseases.



On August 26, 2019, Amgen announced it would acquire Otezla, the only oral, non-biologic treatment for psoriasis and psoriatic arthritis, from Celgene for \$13.4 billion. This comes in the wake of Celgene's merger with Bristol-Myers Squibb which was announced in early 2019, and has been delayed because of antitrust concerns.



On June 25, 2019, AbbVie Inc. announced it will acquire Allergan for approximately \$63 billion. The combined company will consist of several franchises with leading positions across immunology, hematologic oncology, medical aesthetics, neuroscience, eye care, women's health, and virology.